GAMMA Investing’s Aldeyra Therapeutics ALDX Stock Holding History

GAMMA Investing’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$166	Sell	135 -185	-58%	-$295	﹤0.01%	4289
2026 Q2	$682	Sell	320 -797	-71%	-$1.37K	﹤0.01%	3941
2026 Q1	$1.89K	Buy	1,117 +820	+276%	+$3.59K	﹤0.01%	3683
2025 Q4	$1.54K	Sell	297 -757	-72%	-$3.89K	﹤0.01%	3675
2025 Q3	$5.5K	Buy	1,054 +663	+170%	+$3.46K	﹤0.01%	3138
2025 Q2	$1.5K	Sell	391 -293	-43%	-$757	﹤0.01%	3459
2025 Q1	$3.93K	Buy	+684	New	+$4.04K	﹤0.01%	3180
2024 Q4	–	Sell	-25	Closed	-$135	–	3779
2024 Q3	$135	Buy	+25	New	+$119	﹤0.01%	3546

Other funds holding ALDX

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing's ALDX Position: Q3 2026 in Review

GAMMA Investing reduced its Aldeyra Therapeutics (ALDX) stake by 58% in Q3 2026, selling an estimated $295 and leaving 135 shares worth $166. The position accounts for ﹤0.01% of the portfolio, ranked #4289.

GAMMA Investing first reported a position in ALDX in Q3 2024 and has held it in 8 quarters since. The position peaked at $5.5K in Q3 2025. 2 funds tracked by Wall St. Rank hold ALDX as of Q3 2026.

GAMMA Investing held 135 shares of Aldeyra Therapeutics worth $166 as of Q3 2026.
GAMMA Investing sold 185 Aldeyra Therapeutics shares in Q3 2026, an estimated $295.
Aldeyra Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #4289 holding.
GAMMA Investing first reported a position in Aldeyra Therapeutics in Q3 2024 and has held it in 8 quarters since.
GAMMA Investing's Aldeyra Therapeutics position peaked at $5.5K in Q3 2025.
2 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.